Crinetics CEO granted options and RSUs
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings.
Rhea-AI Filing Summary
Crinetics Pharmaceuticals President & CEO Richard Scott Struthers reported equity awards and updated his holdings. He received a stock option for 228,000 shares of Common Stock at an exercise price of $0.00, vesting in forty-eight equal monthly installments starting on February 23, 2026. He also received 62,000 restricted stock units, which vest 25% annually beginning on March 1, 2027. The filing also reflects indirect ownership of Common Stock through four family trusts and a spouse, with separate reported balances for each entity.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 290,000 shares
Grant/Award
7 txns
Insider
Struthers Richard Scott
Role
President & CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 228,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 62,000 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 228,000 contracts (Direct);
Common Stock — 426,759 shares (Direct);
Common Stock — 661,205 shares (Indirect, By Family Trust 1);
Common Stock — 106,000 shares (Indirect, By Family Trust 2);
Common Stock — 110,000 shares (Indirect, By Family Trust 3);
Common Stock — 100,000 shares (Indirect, By Family Trust 4);
Common Stock — 1,000 shares (Indirect, By Spouse)
Footnotes (2)
- F1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 1, 2027.
- F2. The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of February 23, 2026.
FAQ
What equity awards did the CRNX CEO receive in this Form 4 filing?
The CEO received a stock option for 228,000 shares and 62,000 restricted stock units. The option vests monthly over four years, while the RSUs vest 25% annually starting in 2027, aligning compensation with long-term company performance.
How do the new stock options for the CRNX CEO vest over time?
The 228,000-share stock option vests in forty-eight equal monthly installments starting February 23, 2026. This means the CEO gains exercisable option rights gradually over four years, tying potential benefit to continued service and long-term value creation.
What is the vesting schedule for the 62,000 RSUs granted to the CRNX CEO?
The 62,000 restricted stock units vest 25% annually beginning March 1, 2027. Each year, one-quarter of the units converts into shares of Common Stock, creating a multi-year incentive structure focused on future performance and retention.
Are the equity awards to the CRNX CEO open-market purchases or grants?
They are grants, not open-market purchases. Both the 228,000-share stock option and the 62,000 restricted stock units are reported with a transaction code for grant or award, at a stated price of $0.00 per share, reflecting compensatory awards.
AI-generated analysis. How Rhea-AI works. Not financial advice.
